Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2019-08-07 Capital/Financing Update
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement and accompanying prospectus related to an 'At the Market Offering Sales Agreement' for common stock of PTC Therapeutics, Inc. It includes details about the offering, registration fee calculation, sales agents, and legal disclaimers. The document references Securities Act rules and is clearly a capital raising filing. It is not a financial report, earnings release, or management discussion. It is not a proxy, AGM material, or legal proceeding. The document is a detailed offering document for a securities issuance, which fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters) and contains the full offering details, not just an announcement or a brief summary, so it is not an RPA or FS. Therefore, the correct classification is CAP with high confidence.
2019-08-07 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to an At the Market Offering Sales Agreement for selling shares. It includes details about the agreement, parties involved, and legal opinions, but does not contain financial statements or detailed financial performance data. The document is not an annual or quarterly report, earnings release, or management discussion. It is an announcement of a capital raising activity through a sales agreement. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6893 characters, which is sufficient to contain substantive information about the financing event itself, not just a brief announcement or reference to another report.
2019-08-07 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-06 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 6, 2019, reporting the company's financial results for the quarter ended June 30, 2019. It includes a press release and announces a conference call to discuss the quarterly financial results and corporate updates. The document does not contain the full financial statements or detailed financial analysis itself but rather announces and furnishes a press release and references a conference call and slide deck. The length is 4456 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing quarterly results and providing a press release is classified as an Earnings Release (ER).
2019-08-06 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by PTC Therapeutics, Inc. It reports the entry into a material definitive agreement, specifically a lease agreement for office and laboratory space. The document includes details about the lease terms, obligations, and financial commitments but does not contain comprehensive financial statements or detailed financial performance data. It also includes a press release as an exhibit. The Form 8-K is used for reporting significant events and updates rather than full financial reports. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories like Annual Report or Interim Report.
2019-08-05 English
FORM 4
Director's Dealing
2019-07-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.